HUP0300920A1 - Szubsztituált benzidszármazékok és gyógyszerként történő felhasználásuk - Google Patents
Szubsztituált benzidszármazékok és gyógyszerként történő felhasználásukInfo
- Publication number
- HUP0300920A1 HUP0300920A1 HU0300920A HUP0300920A HUP0300920A1 HU P0300920 A1 HUP0300920 A1 HU P0300920A1 HU 0300920 A HU0300920 A HU 0300920A HU P0300920 A HUP0300920 A HU P0300920A HU P0300920 A1 HUP0300920 A1 HU P0300920A1
- Authority
- HU
- Hungary
- Prior art keywords
- group
- alkyl
- halogen atom
- hydrogen
- atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A találmány szubsztituált (I) általános képletű benzamidszármazékokra- amelynek képletében A =NR7 csoport; W oxigén-, kénatom, kéthidrogénatom vagy =NR8 csoport; Z kémiai kötés, =NR10, =N- csoport,alkilcsoport vagy csoport; m, n és o értéke 0, 1, 2 vagy 3; Ra, Rb,Rc, Rd, Re és Rf hidrogén-, fluoratom, alkilcsoport vagy =NR10 csoportés/vagy Ra és/vagy Rb Rc-vel és/vagy Rd-vel vagy Rc Re-vel és/vagy Rf-fel kötést képezhet, vagy Ra-Rf közül legfeljebb kettő az R1-hez vagyR7-hez kapcsolódó, legfeljebb 3 szénatomos hidat képezhet; R1 adottesetben halogénatommal vagy alkilcsoporttal egyszeresen vagytöbbszörösen szubsztituált alkil-, alkenil- alkinil-, cikloalkil- vagycikloalkenilcsoport, vagy adott esetben halogénatommal, alkil-,alkoxi-, halogén-alkil- vagy halogén-alkoxi-csoporttal szubsztituáltaril- vagy heteroarilcsoport; R2 és R3 hidrogénatom, hidroxi- vagyXR11 csoport; X alkil-, alkenil- vagy alkinilcsoport; R11 adottesetben halogénatommal, alkil-, alkoxi- vagy hidroxicsoporttalszubsztituált aril- vagy heteroarilcsoport; R4, R5 és R6 hidrogén-,halogénatom, vagy adott esetben halogénatommal szubsztituált alkoxi-,alkil-, karboxi-alkil-csoport; vagy R4 és R5 közösen csoportot képez;R7 hidrogénatom vagy alkilcsoport, vagy a Z jelentésében szereplő Ra-Rf-fel R1-hez egy legfeljebb három gyűrűtagú hidat képez; R8 és R10hidrogénatom vagy alkilcsoport; valamint izomereire és sóira, továbbáa vegyületek perzisztens angiogenezis által kiváltott betegségekkezelésére szolgáló gyógyszerekként történő felhasználására, valaminta benzamidszármazékok előállítására szolgáló intermedierekrevonatkozik. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10021246A DE10021246A1 (de) | 2000-04-25 | 2000-04-25 | Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel |
PCT/EP2001/004627 WO2001081311A1 (de) | 2000-04-25 | 2001-04-24 | Substituierte benzoesäureamide und deren verwendung zur hemmung von angiogenese |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0300920A1 true HUP0300920A1 (hu) | 2003-07-28 |
Family
ID=7640467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0300920A HUP0300920A1 (hu) | 2000-04-25 | 2001-04-24 | Szubsztituált benzidszármazékok és gyógyszerként történő felhasználásuk |
Country Status (28)
Country | Link |
---|---|
US (1) | US20110009447A1 (hu) |
EP (1) | EP1280776B1 (hu) |
JP (1) | JP2004512259A (hu) |
KR (1) | KR100904101B1 (hu) |
CN (1) | CN1285578C (hu) |
AT (1) | ATE446288T1 (hu) |
AU (2) | AU5227201A (hu) |
BG (1) | BG107212A (hu) |
BR (1) | BR0110246A (hu) |
CA (1) | CA2406392C (hu) |
CZ (1) | CZ20023545A3 (hu) |
DE (2) | DE10021246A1 (hu) |
EE (1) | EE200200609A (hu) |
ES (1) | ES2334433T3 (hu) |
HK (1) | HK1056559A1 (hu) |
HR (1) | HRP20020933A2 (hu) |
HU (1) | HUP0300920A1 (hu) |
IL (1) | IL152292A0 (hu) |
MX (1) | MXPA02010559A (hu) |
NO (1) | NO325445B1 (hu) |
NZ (1) | NZ521681A (hu) |
PL (1) | PL358457A1 (hu) |
RU (1) | RU2353618C2 (hu) |
SK (1) | SK15222002A3 (hu) |
UA (1) | UA82980C2 (hu) |
WO (1) | WO2001081311A1 (hu) |
YU (1) | YU71102A (hu) |
ZA (1) | ZA200209494B (hu) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
RU2006106920A (ru) | 2003-08-06 | 2007-09-20 | Синомикс Инк. (Us) | Гетеро-олигомерные вкусовые рецепторы t1r, клеточные линии, которые экспрессируют указанные рецепторы и вкусовые соединения |
UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
TW200529812A (en) | 2003-12-26 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Benzamide derivatives |
DE102004009238A1 (de) * | 2004-02-26 | 2005-09-08 | Merck Patent Gmbh | Arylamid-Derivate |
US8247556B2 (en) | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
MX343042B (es) | 2005-12-23 | 2016-10-21 | Ariad Pharma Inc | Compuestos heteroarilicos biciclicos. |
DK2010009T3 (en) | 2006-04-21 | 2017-10-02 | Senomyx Inc | PROCEDURES FOR THE PREPARATION OF SOLID FLAVOR COMPOSITIONS |
US7998978B2 (en) | 2006-05-01 | 2011-08-16 | Pfizer Inc. | Substituted 2-amino-fused heterocyclic compounds |
ES2555515T3 (es) | 2006-05-08 | 2016-01-04 | Ariad Pharmaceuticals, Inc. | Compuestos de heteroarilo monocíclico |
EP2023933A4 (en) * | 2006-05-08 | 2011-02-23 | Ariad Pharma Inc | HETEROARYL ACETYLENE COMPOUNDS |
AU2007319151B2 (en) * | 2006-11-16 | 2013-05-23 | Allergan, Inc. | Sulfoximines as kinase inhibitors |
US7858782B2 (en) | 2006-12-15 | 2010-12-28 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
EP2076124A4 (en) | 2007-04-20 | 2011-08-03 | Acucela Inc | STYRENYL DERIVATIVE COMPOUNDS FOR THE TREATMENT OF OPHTHALMOLOGICAL DISEASES AND SUFFERING |
TWI490214B (zh) * | 2008-05-30 | 2015-07-01 | 艾德克 上野股份有限公司 | 苯或噻吩衍生物及該等作為vap-1抑制劑之用途 |
RU2522444C2 (ru) | 2008-08-27 | 2014-07-10 | Лео Фарма А/С | Производные пиридина в качестве ингибиторов рецепторов фактора роста эндотелия сосудов 2 подтипа (vegfr-2) и протеинтирозинкиназы |
JP5590040B2 (ja) | 2008-11-12 | 2014-09-17 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのピラジノピラジンおよび誘導体 |
JP2012513464A (ja) | 2008-12-23 | 2012-06-14 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | ホスホジエステラーゼ阻害剤及びその使用 |
WO2010144550A1 (en) | 2009-06-09 | 2010-12-16 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
US8877924B2 (en) | 2009-06-09 | 2014-11-04 | NantBio Inc. | Benzyl substituted triazine derivatives and their therapeutical applications |
TW201103904A (en) * | 2009-06-11 | 2011-02-01 | Hoffmann La Roche | Janus kinase inhibitor compounds and methods |
BR112013013790A2 (pt) | 2010-12-17 | 2016-09-13 | Hoffmann La Roche | compostos heterocíclos nitrogenosos 6,6-fundidos substituídos e usos dos mesmos |
CA3022250A1 (en) | 2012-12-12 | 2014-06-12 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
KR20160110357A (ko) * | 2013-11-15 | 2016-09-21 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | Ebna1 억제제 및 그의 사용 방법 |
EP3294705B1 (en) | 2015-05-14 | 2021-07-21 | The Wistar Institute Of Anatomy And Biology | Ebna1 inhibitors and methods using same |
CN106740403A (zh) * | 2017-03-21 | 2017-05-31 | 西北工业大学 | 一种液氮动力输出系统及混合动力冷链运输车 |
US11242338B2 (en) | 2018-05-17 | 2022-02-08 | The Wistar Institute | EBNA1 inhibitor crystalline forms, and methods of preparing and using same |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1643265C3 (de) * | 1967-12-22 | 1978-08-31 | C.H. Boehringer Sohn, 6507 Ingelheim | Kernsubstituierte 2-Aminomethylbenzhydrole, Verfahren zu deren Herstellung und Arzneimittel auf der Basis dieser Verbindungen |
JPH02218654A (ja) * | 1988-10-12 | 1990-08-31 | Ono Pharmaceut Co Ltd | 安息香酸誘導体、それらの製造方法およびそれらを含有する薬剤 |
DE19648793A1 (de) * | 1996-11-26 | 1998-05-28 | Basf Ag | Neue Benzamide und deren Anwendung |
US5863455A (en) * | 1997-07-14 | 1999-01-26 | Abb Power T&D Company Inc. | Colloidal insulating and cooling fluid |
WO2000012089A1 (en) * | 1998-08-31 | 2000-03-09 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
JP3013989B2 (ja) * | 1998-03-26 | 2000-02-28 | 日本たばこ産業株式会社 | アミド誘導体及びノシセプチンアンタゴニスト |
CA2336848A1 (en) * | 1998-07-10 | 2000-01-20 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
BR9915139A (pt) * | 1998-11-06 | 2001-08-07 | Basf Ag | Método de inibir a hiperpermeabilidade vascular, e de inibir um processo ou estado fisiológico em um indivìduo |
GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
HN2001000008A (es) * | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
-
2000
- 2000-04-25 DE DE10021246A patent/DE10021246A1/de not_active Withdrawn
-
2001
- 2001-03-24 AU AU5227201A patent/AU5227201A/xx active Pending
- 2001-04-24 RU RU2002130252/04A patent/RU2353618C2/ru not_active IP Right Cessation
- 2001-04-24 PL PL01358457A patent/PL358457A1/xx not_active Application Discontinuation
- 2001-04-24 YU YU71102A patent/YU71102A/sh unknown
- 2001-04-24 CA CA2406392A patent/CA2406392C/en not_active Expired - Fee Related
- 2001-04-24 KR KR1020027014257A patent/KR100904101B1/ko not_active IP Right Cessation
- 2001-04-24 UA UA2002119346A patent/UA82980C2/ru unknown
- 2001-04-24 ES ES01925566T patent/ES2334433T3/es not_active Expired - Lifetime
- 2001-04-24 JP JP2001578406A patent/JP2004512259A/ja active Pending
- 2001-04-24 IL IL15229201A patent/IL152292A0/xx unknown
- 2001-04-24 AT AT01925566T patent/ATE446288T1/de not_active IP Right Cessation
- 2001-04-24 HU HU0300920A patent/HUP0300920A1/hu unknown
- 2001-04-24 WO PCT/EP2001/004627 patent/WO2001081311A1/de active Application Filing
- 2001-04-24 CN CNB018086004A patent/CN1285578C/zh not_active Expired - Fee Related
- 2001-04-24 SK SK1522-2002A patent/SK15222002A3/sk unknown
- 2001-04-24 MX MXPA02010559A patent/MXPA02010559A/es active IP Right Grant
- 2001-04-24 EP EP01925566A patent/EP1280776B1/de not_active Expired - Lifetime
- 2001-04-24 US US10/258,345 patent/US20110009447A1/en not_active Abandoned
- 2001-04-24 BR BR0110246-0A patent/BR0110246A/pt not_active IP Right Cessation
- 2001-04-24 EE EEP200200609A patent/EE200200609A/xx unknown
- 2001-04-24 CZ CZ20023545A patent/CZ20023545A3/cs unknown
- 2001-04-24 DE DE50115189T patent/DE50115189D1/de not_active Expired - Lifetime
- 2001-04-24 AU AU2001252272A patent/AU2001252272B2/en not_active Ceased
- 2001-04-24 NZ NZ521681A patent/NZ521681A/xx unknown
-
2002
- 2002-10-23 BG BG107212A patent/BG107212A/bg unknown
- 2002-10-24 NO NO20025102A patent/NO325445B1/no unknown
- 2002-11-21 ZA ZA200209494A patent/ZA200209494B/en unknown
- 2002-11-25 HR HR20020933A patent/HRP20020933A2/hr not_active Application Discontinuation
-
2003
- 2003-12-09 HK HK03108926A patent/HK1056559A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0300920A1 (hu) | Szubsztituált benzidszármazékok és gyógyszerként történő felhasználásuk | |
HUP0402454A2 (hu) | Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0203122A2 (hu) | Fab I inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0303084A2 (hu) | Gyulladásgátló hatású 17béta-karbotioát-17alfa-arilkarboniloxiloxi androsztán-származékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
HUP0001446A2 (hu) | HIV reverz transzkriptáz inhibitor hatású 4,4-diszubsztituált-3,4-dihidro-2(1H)-kinazolinon-származékok, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0303164A2 (hu) | Kinazolinok mint MMP-13 gátlók, eljárás az előállításukra, intermedierjeik és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0400365A2 (hu) | 3-Fluor-pirrolidinek, mint cukorbetegség elleni szerek és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0102295A2 (hu) | Citokinek által közvetített betegségek kezelésére alkalmas benzamid-származékok | |
HUP0301236A2 (hu) | Szubsztituált kinazolinszármazékok és felhasználásuk inhibitorokként | |
HUP0400202A2 (hu) | Metalloproteináz inhibitor, hatású imidazolidin-dion-származékok alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
HUP0202758A2 (hu) | Izomer kondenzált pirrolokarbazolok és izoindolok és intermedierjeik, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HRP20040317A2 (en) | 1,8-naphthyridine derivatives as antidiabetics | |
HUP0302487A2 (hu) | Új mandulasavszármazékok és felhasználásuk trombin inhibitorokként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0202655A2 (hu) | N-[(amino-imino-metil)- és N-[(amino-metil)-fenil]-propil-amid származékok | |
DK1533292T3 (da) | Dibenzylaminforbindelse og medicinsk anvendelse deraf | |
HUP0401009A2 (hu) | 5-Hidroxitriptamin-6-ligandumokként alkalmazható 1-aril- vagy 1- alkil-szulfonilbenzazol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0102058A2 (hu) | Új 2-alkil-szubsztituált imidazolvegyületek, eljárás előállításukra, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
HUP0001760A2 (hu) | Aril-acil-piridazin-származékok, ezeket a vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és a vegyületek alkalmazása gyógyszerkészítmények előállítására | |
HUP0401638A2 (hu) | Daganatellenes hatású tiofén- és tiazolszulfonamid származékok, valamint ezeket tartalmazó gyógyászati készítmények | |
HUP0100865A2 (hu) | Meta-azaciklusos csoporttal N-szubsztituált amino-benzoesav-vegyületek és származékaik mint integrin antagonista hatóanyagok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0303385A2 (hu) | Szerotonin újrafelvételt inhibeáló fenoxibenzilamin-származékok, előállítási eljárásuk, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
HUP0003577A2 (hu) | Tetrahidro-gamma-karbolinok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
ATE482933T1 (de) | Sulfopyrrolderivate | |
HUP0001093A2 (hu) | 5-HT2A-antagonista oxazolidinon-származékok, az ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
HUP0302616A2 (hu) | Triptaminszármazékok és analóg vegyületek, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC9A | Change of name, address |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE Free format text: FORMER OWNER(S): SCHERING AG., DE |
|
FD9A | Lapse of provisional protection due to non-payment of fees |